Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®)–Health Professional Version

OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCER

SECTIONS

Changes to This Summary (11/18/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Description of the Evidence

Added text to state that a September 2016 safety communication from the U.S. Food and Drug Administration recommends against using currently offered screening tests to screen for ovarian cancer in any population of women.

Added text to state that after transitioning of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial participants to a centralized follow-up process, follow-up for mortality was extended until the end of 2012, for a maximum of 19.2 years and a median of 14.7 years (cited Pinsky et al. as reference 25).

Revised text to state that through the original period of follow-up (maximum, 13 years), 118 deaths were caused by ovarian cancer (3.1 per 10,000 person-years) in the intervention group and 100 deaths were caused by ovarian cancer (2.6 per 10,000 person-years) in the usual-care group; added text to describe mortality rates in the intervention and the usual-care groups through the extended follow-up period of the PLCO trial.

This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Description of the Evidence

Next section >
About This PDQ Summary